332 related articles for article (PubMed ID: 38183103)
1. Current and future therapeutic strategies for high-grade gliomas leveraging the interplay between epigenetic regulators and kinase signaling networks.
Stitzlein LM; Adams JT; Stitzlein EN; Dudley RW; Chandra J
J Exp Clin Cancer Res; 2024 Jan; 43(1):12. PubMed ID: 38183103
[TBL] [Abstract][Full Text] [Related]
2. Pediatric high-grade glioma: aberrant epigenetics and kinase signaling define emerging therapeutic opportunities.
Sun Y; Bailey CP; Sadighi Z; Zaky W; Chandra J
J Neurooncol; 2020 Oct; 150(1):17-26. PubMed ID: 32504402
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic-Targeted Treatments for H3K27M-Mutant Midline Gliomas.
Lu VM; Daniels DJ
Adv Exp Med Biol; 2021; 1283():73-84. PubMed ID: 33155139
[TBL] [Abstract][Full Text] [Related]
4. Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells.
Orzan F; Pellegatta S; Poliani PL; Pisati F; Caldera V; Menghi F; Kapetis D; Marras C; Schiffer D; Finocchiaro G
Neuropathol Appl Neurobiol; 2011 Jun; 37(4):381-94. PubMed ID: 20946108
[TBL] [Abstract][Full Text] [Related]
5. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Chen R; Cohen AL; Colman H
Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
[TBL] [Abstract][Full Text] [Related]
6. Mutations in chromatin machinery and pediatric high-grade glioma.
Lulla RR; Saratsis AM; Hashizume R
Sci Adv; 2016 Mar; 2(3):e1501354. PubMed ID: 27034984
[TBL] [Abstract][Full Text] [Related]
7. Targeting epigenetic regulators for cancer therapy.
Wee S; Dhanak D; Li H; Armstrong SA; Copeland RA; Sims R; Baylin SB; Liu XS; Schweizer L
Ann N Y Acad Sci; 2014 Feb; 1309():30-6. PubMed ID: 24571255
[TBL] [Abstract][Full Text] [Related]
8. Targeting post-translational histone modifying enzymes in glioblastoma.
Kunadis E; Lakiotaki E; Korkolopoulou P; Piperi C
Pharmacol Ther; 2021 Apr; 220():107721. PubMed ID: 33144118
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic modification in gliomas: role of the histone methyltransferase EZH2.
Bian EB; Li J; He XJ; Zong G; Jiang T; Li J; Zhao B
Expert Opin Ther Targets; 2014 Oct; 18(10):1197-206. PubMed ID: 25046371
[TBL] [Abstract][Full Text] [Related]
10. Glioma epigenetics: From subclassification to novel treatment options.
Gusyatiner O; Hegi ME
Semin Cancer Biol; 2018 Aug; 51():50-58. PubMed ID: 29170066
[TBL] [Abstract][Full Text] [Related]
11. Systematic Review of Epigenetic Therapies for Treatment of IDH-mutant Glioma.
Govindarajan V; Shah AH; Di L; Rivas S; Suter RK; Eichberg DG; Luther E; Lu V; Morell AA; Ivan ME; Komotar RJ; Ayad N; De La Fuente M
World Neurosurg; 2022 Jun; 162():47-56. PubMed ID: 35314408
[TBL] [Abstract][Full Text] [Related]
12. Advances on Epigenetic Drugs for Pediatric Brain Tumors.
Skouras P; Markouli M; Strepkos D; Piperi C
Curr Neuropharmacol; 2023; 21(7):1519-1535. PubMed ID: 36154607
[TBL] [Abstract][Full Text] [Related]
13. No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3.
Wiese M; Schill F; Sturm D; Pfister S; Hulleman E; Johnsen SA; Kramm CM
Klin Padiatr; 2016 Apr; 228(3):113-7. PubMed ID: 27135271
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells.
Was H; Krol SK; Rotili D; Mai A; Wojtas B; Kaminska B; Maleszewska M
Clin Epigenetics; 2019 Jan; 11(1):11. PubMed ID: 30654849
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma.
Bailey CP; Figueroa M; Gangadharan A; Yang Y; Romero MM; Kennis BA; Yadavilli S; Henry V; Collier T; Monje M; Lee DA; Wang L; Nazarian J; Gopalakrishnan V; Zaky W; Becher OJ; Chandra J
Neuro Oncol; 2020 Sep; 22(9):1302-1314. PubMed ID: 32166329
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic regulation in human melanoma: past and future.
Sarkar D; Leung EY; Baguley BC; Finlay GJ; Askarian-Amiri ME
Epigenetics; 2015; 10(2):103-21. PubMed ID: 25587943
[TBL] [Abstract][Full Text] [Related]
17. Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase.
Ott M; Litzenburger UM; Sahm F; Rauschenbach KJ; Tudoran R; Hartmann C; Marquez VE; von Deimling A; Wick W; Platten M
PLoS One; 2012; 7(10):e47663. PubMed ID: 23077658
[TBL] [Abstract][Full Text] [Related]
18. Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG.
Anastas JN; Zee BM; Kalin JH; Kim M; Guo R; Alexandrescu S; Blanco MA; Giera S; Gillespie SM; Das J; Wu M; Nocco S; Bonal DM; Nguyen QD; Suva ML; Bernstein BE; Alani R; Golub TR; Cole PA; Filbin MG; Shi Y
Cancer Cell; 2019 Nov; 36(5):528-544.e10. PubMed ID: 31631026
[TBL] [Abstract][Full Text] [Related]
19. Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism.
Morel D; Almouzni G; Soria JC; Postel-Vinay S
Ann Oncol; 2017 Feb; 28(2):254-269. PubMed ID: 28426098
[TBL] [Abstract][Full Text] [Related]
20. Targeting Epigenetic Pathways in the Treatment of Pediatric Diffuse (High Grade) Gliomas.
Vanan MI; Underhill DA; Eisenstat DD
Neurotherapeutics; 2017 Apr; 14(2):274-283. PubMed ID: 28233220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]